KRRO (Korro Bio) ROCE %: -60.46% (As of Mar. 2026)


KRRO Korro Bio Inc KRRO
6 GF Score
Price $12.17
! 4 Warning Signs
View Full Analysis

What is Korro Bio ROCE %?

Korro Bio KRRO -11.68% 6 ROCE % is -60.46% as of Mar. 2026. GuruFocus rates KRRO with a GF Score™ of 6/100. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Korro Bio's annualized ROCE % for the quarter that ended in Mar. 2026 was -60.46%.

Korro Bio  (NAS:KRRO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Korro Bio ROCE % Related Terms

Korro Bio ROCE % Historical Data

* Premium members only.

The historical data trend for Korro Bio's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Korro Bio ROCE % Chart

Korro Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
-28.94 -62.88 -63.27 -44.46 -55.84

Korro Bio Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.96 -61.72 -49.62 -51.14 -60.46
KRRO
6GF Score
Korro Bio Inc KRRO
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Korro Bio ROCE % Calculation

Korro Bio's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-87.342/( ( (226.24 - 14.96) + (113.506 - 11.937) )/ 2 )
=-87.342/( (211.28+101.569)/ 2 )
=-87.342/156.4245
=-55.84 %

Korro Bio's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-81.744/( ( (113.506 - 11.937) + (183.622 - 14.787) )/ 2 )
=-81.744/( ( 101.569 + 168.835 )/ 2 )
=-81.744/135.202
=-60.46 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -60.46% mean?
Korro Bio (KRRO) has a ROCE % of -60.46% as of Mar. 2026.
Is Korro Bio's ROCE % too high?
Korro Bio's current ROCE % is -60.46%. Overall, Korro Bio has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Korro Bio's ROCE % compare to TNYA and ENLV?
Korro Bio's ROCE % of -60.46% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Korro Bio's current ROCE % is -60.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Korro Bio stock overvalued right now?
Korro Bio (KRRO) has a current ROCE % of -60.46%. The current ROCE % is -60.46%. Korro Bio's overall GF Score™ is 6/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Korro Bio (KRRO), the current ROCE % is -60.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Korro Bio Business Description

Address 60 First Street, 2nd Floor, Suite 250, Cambridge, MA, USA, 02141
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
6GF Score

Get the complete analysis for KRRO

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.17
Price